Abstract

AstraZeneca showed remarkable flexibility for a multinational of its size when, at the beginning of the 2007, it announced a strategic review, revealing its intention to focus on active internal growth only in certain key disease areas, while maintaining a number of its current therapy areas, but exiting from a total of seven others...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018